Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Infectious Disease
•
Tuberculosis
When is drug-level monitoring helpful in the treatment of pan-susceptible tuberculosis on a standard four-drug therapy regimen?
Related Questions
For how long do you recommend treatment for latent tuberculosis prior to initiation of anti-TNF therapy?
Do you have a preference between Quantiferon Gold and T-spot TB for screening in patients starting immunosuppressive agents?
For which patients or under which circumstances do you recommend a 9-month over a 6-month course of isoniazid for treatment of LTBI?
If a patient does not tolerate completion of a course of LTBI treatment with either 6-9INH or 3HP, is it reasonable to complete a subsequent partial course of rifampin alone, or does the rifampin treatment course need to be re-started?
Does your institution have formal policies or work flows to reduce unnecessary IGRAs ordered for patients on biologics?
How do you approach treatment of tuberculous scleritis in pregnancy?
How do you approach a positive Quantiferon/PPD test result in a patient for whom testing is sent without a clinical indication and who does not have a risk factor for TB exposure nor TB reactivation?
How do you approach a patient who has anterior uveitis and is referred for evaluation of ocular TB with a positive Quantiferon gold (as part of their workup) in countries with low TB incidence?
How do you approach ongoing screening for TB in patients with a history of treated latent TB, but who have ongoing use of DMARDs and/or biologics given Quantiferon testing and PPD can remain positive?
What is the preferred four-drug regimen for initial treatment of pan-susceptible tuberculous meningitis, given the need to achieve optimal CNS penetration?
